ArticleDiscover oncology2025
Exploring ASPN as a pan-cancer biomarker with a focus on gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ANP32A interacts with LDHA to modulate glycolysis and ferroptosis in hepatocellular carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCancer remains a leading cause of mortality worldwide, posing a serious threat to public health. The ASPN protein has emerged as a key player in certain cancers; however, its precise mechanisms and regulatory roles are still not well-defined.
methodsWe explored the expression of ASPN and its prognostic significance across various cancers. Functional enrichment analyses were conducted using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO). The association between ASPN expression and factors including immune cell infiltration, immune checkpoint genes, microsatellite instability (MSI), tumor mutational burden (TMB), drug sensitivity, promoter methylation, and tumor mutation types was examined. Finally, the function of ASPN in stomach adenocarcinoma (STAD) was examined using RT-qPCR, WB, Cell Counting Kit-8, Transwell, scratch, and flow cytometry assays, focusing on the effects of ASPN on cell proliferation, migration, invasion, and apoptosis.
resultsASPN expression was high in several cancers, where higher expression correlated with poorer prognosis. Gene enrichment analysis indicates ASPN is involved in several cellular pathways and correlates with immune cells infiltration, TMB, and MSI. The single-cell analysis showed that ASPN was mainly expressed in fibroblasts, and ASPN mutations predominantly consisted of missense mutations. After using siRNA knockdown of ASPN, CCK-8 assay and wound healing assays exhibited that suppressed cell viability and migration ability of gastric cells, Transwell assay displayed migration and invasion abilities of two gastric cell lines was decreased. In accordance with the result of cell apoptosis, reducing ASPN elevated the rate of apoptosis in two gastric cancer cells. ASPN inhibition leads to upregulation of pro-apoptotic BAX and cleaved Caspase-3, and downregulation of anti-apoptotic BCL2. These findings suggest that ASPN contributes to gastric cancer aggressiveness.
conclusionElevated ASPN expression across cancers is associated with poorer prognosis, highlighting its potential as a prognostic biomarker and therapeutic target, particularly in gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.